Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma,
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D.
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health -led Phase 2 study in chronic spontaneous
Proven immunology-focused executive and physician-scientist who has led companies from inception to IPO, driven multiple regulatory approvals, and helped build multi-billion-dollar therapeutic portfolios BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today
Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases